RMOC Recommendation: Standardising strengths of high risk, unlicensed oral liquids formulations for anti-TB medicines

At the meeting on 26th October 2017 the Regional Medicines Optimisation Committee (North) endorsed the approach put forward by the NHS Pharmaceutical Quality Assurance Committee Sub-Group on Unlicensed Medicines to standardise the strengths of high risk unlicensed oral liquids for anti- TB medicines.

IsoniazidPyrazinamideRifampicin + IsoniazidRifampicin + Isoniazid + PyrazinamideRMOC medicines optimisation recommendations and resources

Attachments